---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-004843"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-01-24T23:59:59+00:00"
generated_at: "2026-06-20T10:56:50.343471+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Jasper Therapeutics posts updated corporate presentation highlighting c-Kit approach and briquilimab

## Summary
- Filed an updated corporate presentation (Exhibit 99.1) dated January 2023 under Item 7.01.
- Presentation titled 'Harnessing the Power of Jasper’s Differentiated c-Kit Therapeutic Approach'.
- Briquilimab described as an investigative drug not approved for any indication.
- No specific financial or clinical updates provided in the furnished exhibit.

## SEC filing metadata
- accession: 0001213900-23-004843
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-01-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390023004843/0001213900-23-004843-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390023004843/ea172105-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-004843
- JSON: https://secwatch.observer/filing/0001213900-23-004843.json
- Plain text: https://secwatch.observer/filing/0001213900-23-004843.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.